The efficacy of calcitriol treatment in non-alcoholic fatty liver patients with different genotypes of vitamin D receptor FokI polymorphism.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of fatty liver & elevated liver enzymes, published as a randomized controlled trial.

Vitamin D deficiency is prevalent in patients with non-alcoholic fatty liver disease (NAFLD), but there are debates on the usefulness of vitamin D treatment.

The interindividual variations in response may be due to different genetic backgrounds.

Who Took Part

According to the abstract, 128 patients were involved.

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

The ARMS-PCR method was used to genotype the VDR FokI polymorphism.

What Was Measured

PubMed files the paper under topics including Calcitriol, Genotype, Non-alcoholic Fatty Liver Disease, Polymorphism, Genetic, Receptors, Calcitriol and Vitamins.

Author keywords: FokI polymorphism and Vitamin D receptor.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 128 patients in people with fatty liver & elevated liver enzymes.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (BMC pharmacology & toxicology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Fatty liver & elevated liver enzymes research.